← Oncology Approval Tracker

FDA DECISION ·

Datroway

datopotamab deruxtecan-dlnk · Daiichi Sankyo

Accelerated approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with locally advanced or metastatic EGFR-mutated NSCLC previously treated with EGFR-directed therapy and platinum-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

Accelerated approval extended this TROP2 antibody–drug conjugate to a heavily pretreated EGFR-mutated lung cancer population.

What research teams should watch

Verify prior EGFR-targeted therapy and platinum exposure, and specify who triages new pulmonary symptoms.

PRIMARY RECORDS

Sources